X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (60) 60
index medicus (54) 54
male (53) 53
oncology (53) 53
aged (52) 52
female (52) 52
middle aged (50) 50
basic electric elements (39) 39
electricity (39) 39
capacitors (37) 37
capacitors, rectifiers, detectors, switching devices orlight-sensitive devices, of the electrolytic type (37) 37
chemotherapy (37) 37
medicine & public health (34) 34
adult (33) 33
general tagging of cross-sectional technologies spanning over several sections of the ipc (33) 33
general tagging of new technological developments (33) 33
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (33) 33
retrospective studies (29) 29
cancer (28) 28
reduction of greenhouse gas [ghg] emissions, related to energygeneration, transmission or distribution (24) 24
surgical oncology (24) 24
technologies or applications for mitigation or adaptation againstclimate change (24) 24
treatment outcome (24) 24
chemistry (23) 23
gastric cancer (23) 23
compositions based thereon (22) 22
macromolecular compounds obtained otherwise than by reactionsonly involving unsaturated carbon-to-carbon bonds (22) 22
metallurgy (22) 22
organic macromolecular compounds (22) 22
their preparation or chemical working-up (22) 22
antineoplastic combined chemotherapy protocols - therapeutic use (19) 19
prognosis (19) 19
stomach cancer (19) 19
care and treatment (18) 18
cancer research (17) 17
cisplatin (17) 17
disease-free survival (17) 17
drug combinations (17) 17
stomach neoplasms - drug therapy (17) 17
stomach neoplasms - pathology (17) 17
electric solid state devices not otherwise provided for (16) 16
semiconductor devices (16) 16
use of inorganic or non-macromolecular organic substances ascompounding ingredients (16) 16
colorectal cancer (15) 15
metastasis (15) 15
patients (15) 15
s-1 (15) 15
surgery (15) 15
survival (15) 15
aged, 80 and over (14) 14
cisplatin - administration & dosage (14) 14
gastroenterology & hepatology (14) 14
processes or means, e.g. batteries, for the direct conversionof chemical into electrical energy (14) 14
tumors (14) 14
climate change mitigation technologies in the production orprocessing of goods (13) 13
fluorouracil (13) 13
japan (13) 13
oxaliplatin (13) 13
analysis (12) 12
antineoplastic combined chemotherapy protocols - adverse effects (12) 12
camptothecin - administration & dosage (11) 11
camptothecin - analogs & derivatives (11) 11
colorectal neoplasms - drug therapy (11) 11
drug therapy (11) 11
gastroenterology (11) 11
5-fluorouracil (10) 10
adenocarcinoma - pathology (10) 10
antimitotic agents (10) 10
antineoplastic agents (10) 10
antineoplastic agents - administration & dosage (10) 10
cancer patients (10) 10
cancer therapies (10) 10
oxonic acid - administration & dosage (10) 10
tegafur - administration & dosage (10) 10
therapy (10) 10
abdominal surgery (9) 9
fluorouracil - administration & dosage (9) 9
irinotecan (9) 9
neoplasm staging (9) 9
radiotherapy (9) 9
research (9) 9
technical subjects covered by former us classification (9) 9
technical subjects covered by former uspc (9) 9
adenocarcinoma (8) 8
adenocarcinoma - drug therapy (8) 8
complications and side effects (8) 8
leucovorin (8) 8
lung cancer (8) 8
supportive care (8) 8
survival analysis (8) 8
survival rate (8) 8
antineoplastic combined chemotherapy protocols - administration & dosage (7) 7
apparatus therefor (7) 7
cables (7) 7
clinical trials (7) 7
colorectal neoplasms - pathology (7) 7
combination (7) 7
conductors (7) 7
diagnosis (7) 7
drug administration schedule (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gastric Cancer, ISSN 1436-3291, 1/2016, Volume 19, Issue 1, pp. 183 - 191
This study was conducted to investigate whether human epidermal growth factor receptor 2 (HER2) status, epidermal growth factor receptor (EGFR) status, and... 
Gastroesophageal junction cancer | Medicine & Public Health | Human epidermal growth factor receptor 2 | Gastroenterology | Abdominal Surgery | Oncology | Cancer Research | c-MET | Surgical Oncology | Gastric cancer | Epidermal growth factor receptor | 1ST-LINE TREATMENT | CLINICAL-FEATURES | LABEL PHASE-3 TRIAL | GROWTH-FACTOR RECEPTOR | OVEREXPRESSION | ONCOLOGY | DOUBLE-BLIND | CARCINOMAS | ESOPHAGOGASTRIC JUNCTION | GASTROENTEROLOGY & HEPATOLOGY | GENE COPY NUMBER | EXPRESSION | Proto-Oncogene Proteins c-met - metabolism | Receptor, Epidermal Growth Factor - genetics | Adenocarcinoma - pathology | Prognosis | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Receptor, ErbB-2 - metabolism | Male | Stomach Neoplasms - pathology | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Receptor, Epidermal Growth Factor - metabolism | Biomarkers, Tumor - metabolism | Esophageal Neoplasms - mortality | Female | Adenocarcinoma - genetics | Retrospective Studies | Stomach Neoplasms - genetics | Esophagogastric Junction - pathology | Oxonic Acid - administration & dosage | Stomach Neoplasms - drug therapy | Proto-Oncogene Proteins c-met - genetics | Esophageal Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Aged | Biomarkers, Tumor - genetics | Stomach Neoplasms - mortality | Drug Combinations | Adenocarcinoma - mortality | Immunohistochemistry | Cancer patients | Care and treatment | Chemotherapy | Patient outcomes | Analysis | Cytogenetics | Stomach cancer | Formaldehyde | Cancer
Journal Article
Cancer Science, ISSN 1347-9032, 09/2014, Volume 105, Issue 9, pp. 1176 - 1181
This study analyzed outcomes of systemic chemotherapy for advanced neuroendocrine carcinoma (NEC) of the digestive system. Clinical data from 258 patients with... 
neuroendocrine carcinoma | digestive system | etoposide | irinotecan | Cisplatin | Etoposide | Irinotecan | Digestive system | Neuroendocrine carcinoma | DIAGNOSIS | ETOPOSIDE/CISPLATIN | MANAGEMENT | CELL LUNG-CANCER | PHASE-III TRIAL | CONSENSUS GUIDELINES | IRINOTECAN/CISPLATIN | ONCOLOGY | EXPERIENCE | Leucovorin - administration & dosage | Prognosis | Gastrointestinal Neoplasms - drug therapy | Gastrointestinal Neoplasms - mortality | Humans | Male | Cisplatin - administration & dosage | Gastrointestinal Neoplasms - pathology | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Camptothecin - administration & dosage | Female | Retrospective Studies | Camptothecin - analogs & derivatives | Carcinoma, Neuroendocrine - mortality | Carcinoma, Neuroendocrine - drug therapy | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Neuroendocrine - pathology | Deoxycytidine - analogs & derivatives | Antimitotic agents | Chemotherapy | Carcinoma | Analysis | Gastrointestinal system | Antineoplastic agents | Cancer | Dehydrogenases | Clinical trials | Multivariate analysis | Intestine | Pancreas | Stomach | Medical research | Research & development--R&D | Histology | Gastrointestinal tract | Survival | Patients | L-Lactate dehydrogenase | Esophagus | Medicine | Hospitals | Medical prognosis | Lactic acid | Neuroendocrine tumors | Pharmaceuticals | Original
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 99 - 108
Journal Article
Journal Article
Digestive Endoscopy, ISSN 0915-5635, 07/2016, Volume 28, Issue 5, pp. 526 - 533
Journal Article
International Journal of Clinical Oncology, ISSN 1341-9625, 12/2018, Volume 23, Issue 6, pp. 1084 - 1089
Although oxaliplatin 130 mg/m2 every 3 weeks was approved for advanced gastric cancer in Japan, data regarding S-1 plus oxaliplatin 130 mg/m2 (SOX130) are... 
Oxaliplatin | Medicine & Public Health | Japanese study | Oncology | Cancer Research | Surgical Oncology | Advanced gastric cancer | SOX
Journal Article
Gastric Cancer, ISSN 1436-3291, 3/2018, Volume 21, Issue 2, pp. 338 - 344
Journal Article
BMC Cancer, ISSN 1471-2407, 05/2018, Volume 18, Issue 1, pp. 573 - 7
Journal Article
Gastric Cancer, ISSN 1436-3291, 7/2016, Volume 19, Issue 3, pp. 894 - 901
Journal Article
Journal Article
Gastric Cancer, ISSN 1436-3291, 11/2018, Volume 21, Issue 6, pp. 1041 - 1049
Ramucirumab, a monoclonal antibody vascular endothelial growth factor receptor-2 antagonist, given as monotherapy improved survival in a global phase 3 study... 
Adenocarcinoma | Medicine & Public Health | REGARD | Japan | Gastroenterology | Abdominal Surgery | Oncology | Cancer Research | Ramucirumab | Pharmacokinetics | Surgical Oncology | Stomach neoplasms | RAINBOW | SAFETY | CANCER | CHEMOTHERAPY | DRUG-DRUG INTERACTION | PACLITAXEL | ONCOLOGY | DOUBLE-BLIND | IRINOTECAN | GASTROENTEROLOGY & HEPATOLOGY | Adenocarcinoma - pathology | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - pharmacokinetics | Esophagogastric Junction - pathology | Antibodies, Monoclonal - therapeutic use | Male | Stomach Neoplasms - pathology | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Esophageal Neoplasms - pathology | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Esophageal Neoplasms - mortality | Adult | Female | Aged | Esophageal Neoplasms - drug therapy | Stomach Neoplasms - mortality | Adenocarcinoma - mortality | Complications and side effects | Medical research | Care and treatment | Chemotherapy | Endothelial growth factors | Monoclonal antibodies | Medicine, Experimental | Development and progression | Metastasis | Cancer | Appetite | Intravenous administration | Diarrhea | Hemorrhage | Cancer therapies | Disease control | Stomach cancer | Survival | Patients | Vascular endothelial growth factor receptors | Metastases | Platinum | Vascular endothelial growth factor | Gastric cancer | Proteinuria
Journal Article
International Journal of Clinical Oncology, ISSN 1341-9625, 6/2015, Volume 20, Issue 3, pp. 455 - 462
Journal Article
by Fuchs, Charles S and Shitara, Kohei and Di Bartolomeo, Maria and Lonardi, Sara and Al-Batran, Salah-Eddin and Van Cutsem, Eric and Ilson, David H and Alsina, Maria and Chau, Ian and Lacy, Jill and Ducreux, Michel and Mendez, Guillermo Ariel and Alavez, Alejandro Molina and Takahari, Daisuke and Mansoor, Wasat and Enzinger, Peter C and Gorbounova, Vera and Wainberg, Zev A and Hegewisch-Becker, Susanna and Ferry, David and Lin, Ji and Carlesi, Roberto and Das, Mayukh and Shah, Manish A and Luft, Alexander V and Karaseva, Nina A and Kowalyszyn, Rubén Dario and Hernandez, Carlos Alberto and Csoszi, Tibor and De Vita, Ferdinando and Pfeiffer, Per and Sugimoto, Naotoshi and Kocsis, Judit and Csilla, Andràs and Bodoky, Gyorgy and Garnica Jaliffe, Georgina and Protsenko, Svetlana and Madi, Ayman and Wojcik, Elzbieta and Brenner, Baruch and Folprecht, Gunnar and Sarosiek, Tomasz and Peltola, Katriina Johanna and Bono, Peter and Ayala, Hubert and Aprile, Giuseppe and Gerardo, Cardellino Giovanni and Huitzil Melendez, Fidel David and Falcone, Alfredo and Di Costanzo, Francesco and Tehfe, Moustapha and Mineur, Laurent and García Alfonso, Pilar and Obermannova, Radka and Senellart, Hélène and Petty, Russell and Samuel, Leslie and Acs, Peter Istvan and Hussein, Maen Abdelkarim and Nechaeva, Marina N and Erdkamp, F.L.G and Won, Elizabeth and Bendell, Johanna Chock and Gallego Plazas, Javier and Lorenzen, Sylvie and Melichar, Bohuslav and Escudero, Miguel Angel and Pezet, Denis and Phelip, Jean-Marc and Kaen, Diego Lucas and Reeves, James A. Jr and Longo Muñoz, Federico and Madhusudan, Srinivasan and Barone, Carlo and Fein, Luis Enrique and Gomez Villanueva, Angel and Hebbar, Mohamed and Prausova, Jana and Visa Turmo, Laura and Vidal Barrull, Joana and Yilmaz, Mette Karen Nytoft and Beny, Alex and Van Laarhoven, H.M.W and DiCarlo, Brian Anthony and Esaki, Taito and Fujitani, Kazumasa and Geboes, Karen and Geva, Ravit and Kadowaki, Shigenori and Leong, Stephen and Machida, Nozomu and Raj, Moses Sundar and Ramirez Godinez, Francisco Javier and Ruzsa, Agnes and Ford, Hugo and Lawler, William E and Maisey, Nicolas Robert and Petera, Jiri and Shacham-Shmueli, Einat and Sinapi, Isabelle and ... and RAINFALL Study Grp and RAINFALL Study Group
The Lancet Oncology, ISSN 1470-2045, 03/2019, Volume 20, Issue 3, pp. 420 - 435
VEGF and VEGF receptor 2 (VEGFR-2)-mediated signalling and angiogenesis can contribute to the pathogenesis and progression of gastric cancer. We aimed to... 
EXPOSURE-RESPONSE | MULTICENTER | GASTROESOPHAGEAL JUNCTION | ANGIOGENESIS | ONCOLOGY | BEVACIZUMAB | COMBINATION | CANCER | EXPRESSION | CHEMOTHERAPY | ENDOTHELIAL GROWTH-FACTOR | Adenocarcinoma | Antimitotic agents | Care and treatment | Analysis | Clinical trials | Product development | Metastasis | Antineoplastic agents | Rain and rainfall
Journal Article